reviewed april 2026|next review october 2026|88 physicians psi has verified|10281 published studies
GDF-15
GDF-15 (Growth Differentiation Factor 15) is a naturally occurring (the body's own) stress-responsive member of the TGF-beta superfamily that suppresses appetite through brainstem GFRAL receptor activation, with dual therapeutic potential as an agonist for obesity and an antagonist for cancer cachexia.
Evidence landscape: 10281 published studies
Published studies span obesity pharmacology, pregnancy biology, cancer cachexia, and metformin mechanism research. Strong mechanistic validation with early-stage clinical development.
- 8 Human
- 166 Animal
- 26 Reviews
- 10081 Other research
No GDF-15-based drug is FDA-approved. Multiple pharmaceutical companies are developing GDF-15 modulators. Agonists for obesity appetite suppression and antagonists for cancer cachexia are in early-to-mid clinical development.
No GDF-15-based therapeutic is commercially available. GDF-15 is a naturally occurring (the body's own) protein. Circulating levels are measurable as a biomarker and are elevated by exercise, metformin, pregnancy, and cancer.
GDF-15 acts through the GFRAL receptor, which is expressed exclusively in the brainstem (area postrema and nucleus of the solitary tract). This is an entirely independent appetite suppression pathway from GLP-1 drugs. The dual-direction therapeutic potential (agonists for obesity, antagonists for cachexia) is unique among metabolic targets.
PSI Assessment
The next major appetite suppression target after GLP-1 may not work through the gut or hypothalamus at all. GDF-15 acts on the GFRAL receptor in the brainstem, the part of the brain that controls nausea and aversion. Three independent research groups identified this receptor in 2017. The biology explains morning sickness (placental GDF-15 rises in pregnancy), cancer wasting (tumors secrete GDF-15), and part of how metformin causes weight loss. Multiple pharmaceutical companies are developing GDF-15 modulators. The critical drug design challenge: separating appetite suppression from nausea.
Independent appetite pathway from GLP-1. GFRAL receptor expressed only in the brainstem. Explains morning sickness, cancer cachexia, and metformin's weight effects. Drug development challenge: appetite suppression without nausea.
The mechanism centers on GFRAL (GDNF Family Receptor Alpha-Like), a receptor expressed exclusively in hindbrain neurons of the area postrema and nucleus tractus solitarius. GDF-15 binds GFRAL, which signals through the RET co-receptor to suppress food intake, reduce body weight, and shift food preferences away from high-fat diets. This pathway is completely independent of GLP-1 signaling. Circulating GDF-15 levels rise during pregnancy (placental production), cancer (tumor secretion), metformin use (mitochondrial stress signaling), and exercise.
What the evidence supports
The GDF-15/GFRAL pathway is established as an appetite regulator by three independent research groups (2017). The morning sickness connection is supported by genetic and mechanistic evidence: placental GDF-15 production rises in pregnancy, and women with genetic variants producing higher baseline GDF-15 have less severe nausea. Cancer cachexia association is documented. Metformin's weight effects are partially mediated through GDF-15 signaling. The biology is compelling and reproducible.
What is not yet established
Whether GDF-15-based drugs can suppress appetite without inducing nausea, the critical drug design challenge. Clinical-stage therapeutic efficacy for any indication (no late-stage trials). Long-term safety of sustained GDF-15 modulation. Whether GDF-15 agonists will complement or compete with GLP-1 drugs. Whether GDF-15 antagonists can reverse cancer cachexia in clinical settings.
Research Evidence
The findings below cover the GFRAL receptor discovery, the pregnancy/morning sickness connection, the cancer cachexia biology, and the metformin mechanism.
Evidence by condition
Evidence dimensions across obesity, cachexia, pregnancy nausea, and biomarker research. Mechanistic evidence is the deepest. Clinical therapeutic data is early-stage.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Obesity Drug Development | ||||
| Cancer Cachexia | ||||
| Cardiovascular Biomarker | ||||
| Pregnancy Nausea (Morning Sickness) |
Three independent research groups simultaneously identified GFRAL as the GDF-15 receptor in 2017. GFRAL is expressed exclusively in the brainstem area postrema and nucleus of the solitary tract, establishing GDF-15/GFRAL as a brainstem-localized appetite suppression pathway independent of GLP-1.
The triple-independent discovery is strong validation. The brainstem-localized receptor expression means GDF-15 targets a fundamentally different appetite control circuit than GLP-1 drugs.
GDF-15 levels directly correlate with nausea severity in pregnancy. Women with genetic variants producing higher baseline GDF-15 (and therefore greater desensitization) experience less severe morning sickness. Placental GDF-15 production rises dramatically in early pregnancy.
This genetic evidence establishes a causal link between GDF-15 and pregnancy nausea. The desensitization finding suggests that pre-exposure could reduce the nausea side effect of GDF-15-based drugs.
GDF-15 knockout mice do not lose weight on metformin, confirming that GDF-15 mediates a significant portion of metformin's appetite-suppressive and weight loss effects through mitochondrial stress signaling.
This discovery reframes metformin pharmacology. Part of the most widely prescribed diabetes drug's weight effects operate through GDF-15/GFRAL rather than through direct metabolic mechanisms.
8 Human|166 Animal|26 Reviews
View all 10281 indexed studiesHow GDF-15 Works
GDF-15 is a naturally occurring (the body's own) divergent member of the TGF-beta superfamily. It binds exclusively to the GFRAL receptor in the brainstem, signaling through the RET co-receptor to suppress appetite, reduce body weight, and alter food preferences.
GDF-15 works differently from GLP-1 drugs. Instead of acting on the gut and hypothalamus, GDF-15 acts on a specific receptor (GFRAL) in the brainstem, the part of the brain that controls nausea and aversion. This is why high GDF-15 causes loss of appetite during pregnancy (morning sickness), cancer, and illness. The drug development approach is to harness this appetite suppression without the nausea.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
GDF-15 is a divergent member of the TGF-beta superfamily. It binds exclusively to the GFRAL receptor (expressed only in area postrema and nucleus tractus solitarius of the brainstem), signaling through RET co-receptor. GFRAL activation reduces food intake, body weight, and preference for high-fat foods. Circulating GDF-15 levels are elevated in pregnancy, cancer cachexia, metformin use, and exercise.
What is GDF-15 being studied for?
Researchers are studying GDF-15 across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for GDF-15 overall. This means a compound can have human studies for one condition but only animal data for another.
Obesity Drug Development
·Human TrialsGDF-15 agonists are in clinical development by multiple pharmaceutical companies as a new class of appetite suppressant acting through a mechanism independent of GLP-1. Animal model (animal research) data shows significant weight reduction.
Limitations: No GDF-15-based drug is in late-stage clinical trials. Whether appetite suppression can be achieved without nausea is the key open question. The therapeutic window between appetite suppression and emesis has not been defined clinically.
Cancer Cachexia
·Animal StudiesElevated GDF-15 drives the appetite loss and wasting seen in many cancers. Anti-GDF-15 antibodies restored appetite and weight in animal cancer models (animal research). GDF-15 antagonists are in early clinical development for cachexia.
Limitations: Anti-GDF-15 therapy for cancer cachexia is investigational. Early-phase clinical trials are underway but efficacy data is limited.
Cardiovascular Biomarker
·Human TrialsElevated GDF-15 levels correlate with cardiovascular risk and mortality in multiple large cohort studies. GDF-15 is being evaluated as a prognostic biomarker in heart failure and acute coronary syndromes.
Limitations: The biomarker association does not establish therapeutic relevance. Whether lowering GDF-15 improves cardiovascular outcomes is unknown.
Pregnancy Nausea (Morning Sickness)
·Animal StudiesGDF-15 levels directly correlate with nausea severity in pregnancy. Genetic evidence supports a causal link. The desensitization hypothesis suggests that pre-exposure reduces severity.
Limitations: Anti-GDF-15 therapy for morning sickness is theoretical. Blocking GDF-15 during pregnancy could have unknown effects on placental function and fetal development.
Safety and Regulatory Status
FDA Status: No GDF-15-based drug is FDA-approved. Agonists for obesity and antagonists for cachexia are in early-to-mid clinical development by multiple pharmaceutical companies.
Availability: No GDF-15-based therapeutic is commercially available. GDF-15 is a naturally occurring (the body's own) protein measurable as a biomarker in standard clinical laboratories.
Class context: The primary safety concern for GDF-15 agonists is nausea, which is inherent to the GFRAL brainstem mechanism. For antagonists, the concern is whether blocking GDF-15 in cancer patients could promote tumor growth or other adverse effects. Both directions require careful clinical evaluation.
GDF-15 is a naturally occurring (the body's own) protein. The therapeutic challenge is that appetite suppression and nausea are mediated by the same brainstem pathway. Separating these effects is the central drug design problem.
Questions and Comparisons
Questions the evidence raises for a GDF-15 discussion.
Comparison and Related Research
GDF-15 is compared with other appetite suppression targets and metabolic signaling pathways.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Identification of GFRAL as the exclusive receptor for GDF-15 in the brainstem area postrema and nucleus tractus solitarius. This study demonstrated that the appetite-suppressing and weight-reducing effects of GDF-15 require GFRAL signaling, establishing the molecular pathway responsible for the metabolic actions of this cytokine.Mullican SE et al., 2017 in Nat Med. View on PubMed
- 2.Complementary study confirming GFRAL as the GDF-15 receptor and demonstrating that GDF-15 administration reduces food intake and body weight in both mice and nonhuman primates. The weight loss was mediated entirely through the brainstem GFRAL pathway, not through peripheral mechanisms.Yang L et al., 2017 in Nat Med. View on PubMed
- 3.Comprehensive review establishing GDF-15 as a cardiovascular biomarker. Elevated circulating GDF-15 levels predict mortality and adverse events in heart failure, acute coronary syndromes, and the general population. The review explored the dual nature of GDF-15 as both a stress-response signal and a potential therapeutic target.Wollert KC et al., 2017 in Clin Chem. View on PubMed
- 4.Review of GDF-15's role in cancer biology and immune evasion. Tumors upregulate GDF-15 to suppress natural killer cell and T-cell activity, creating an immunosuppressive environment. The paper positioned GDF-15 neutralization as a potential immunotherapy strategy, complementing checkpoint inhibitor approaches.Wischhusen J et al., 2020 in Trends Cancer. View on PubMed
- 5.Study demonstrating that GDF-15 levels rise dramatically during chemotherapy and mediate treatment-induced anorexia and nausea through GFRAL activation in the brainstem. Blocking GDF-15 signaling in preclinical models reduced chemotherapy-associated weight loss and emesis, suggesting a therapeutic approach to cancer-related cachexia.Tsai VW et al., 2019 in Cell Metab. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.